Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


The Microemulsion Drug Ocular Penetration System (MiDROPS™) is a transformative technology for the development of eyedrop formulations.  This patented platform allows for the preparation and delivery of lipophilic agents to tissues in both the front and back of the eye.  MiDROPS™ are prepared using materials already approved by the US Food and Drug Administration for use in ophthalmic products, and by nature are intrinsically thermo-stable.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

New Skin Patch Monitors Glucose and Delivers Diabetes Drugs

People with diabetes need to closely monitor their blood glucose levels multiple times every day, … Read More

Research points towards new blindness prevention methods in diabetic eye disease

By combining data on optometry patient's eyes with advanced computational methods, Indiana … Read More

Detecting diabetic eye disease with machine learning

Diabetic retinopathy — an eye condition that affects people with diabetes — is the fastest growing … Read More

More News

Monday, March 27th, 2017 at 2:11pm
Streamlined Development Process for Certain New Drug Applications Is Not Facilitating Shorter Approval Times https://t.co/QETcEGGEDU
Monday, March 27th, 2017 at 3:42am
EU recommends suspending hundreds of drugs tested by Indian firm https://t.co/Ni44yNHFIm
Thursday, March 23rd, 2017 at 10:48am
Study identifies therapeutic target for diabetic retinopathy. https://t.co/AzvKmG5Drm
Monday, March 20th, 2017 at 7:01am
Ischemic injury leads to extracellular matrix alterations in retina and optic nerve https://t.co/iA4BmdaHRo
Ophthalmic Contract Research